RT Journal Article
SR Electronic
T1 SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.10.21260232
DO 10.1101/2021.07.10.21260232
A1 Vimvara Vacharathit
A1 Pakorn Aiewsakun
A1 Suwimon Manopwisedjaroen
A1 Chanya Srisaowakarn
A1 Thanida Laopanupong
A1 Natali Ludowyke
A1 Angsana Phuphuakrat
A1 Chavachol Setthaudom
A1 Supanuch Ekronarongchai
A1 Sirawat Srichatrapimuk
A1 Pattama Wongsirisin
A1 Suleeporn Sangrajrang
A1 Thanarath Imsuwansri
A1 Suppachok Kirdlarp
A1 Sureeporn Nualkaew
A1 Insee Sensorn
A1 Waritta Sawaengdee
A1 Nuanjun Wichukchinda
A1 Somnuek Sungkanuparph
A1 Wasun Chantratita
A1 Mongkol Kunakorn
A1 Jinda Rojanamatin
A1 Suradej Hongeng
A1 Arunee Thitithanyanont
YR 2021
UL http://medrxiv.org/content/early/2021/07/14/2021.07.10.21260232.abstract
AB Recent surges in SARS-CoV-2 variants of concern (VOCs) call for the need to evaluate levels of vaccine-and infection-induced SARS-CoV-2 neutralizing antibodies (NAbs). CoronaVac (Sinovac Biotech, Beijing, China) is currently being used for mass vaccination in Thailand as well as other low-income countries. Three VOCs currently circulating within Thailand include the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) strains. We assessed NAb potency against the prototypic strain containing the original spike sequence (WT) compared to that against the 3 VOCs using sera derived from a cohort of healthcare workers who received a full 2-dose regimen of CoronaVac. Sera from two other cohorts consisting of COVID-19 patients who had been hospitalized in 2020 and 2021 were evaluated for comparison. We found that, despite equally robust production of S1-RBD-binding IgG and 100% seropositivity, sera from both CoronaVac vaccinees and naturally infected individuals had significantly reduced neutralizing capacity against all 3 VOCs compared to WT. Strikingly, NAb titers against Alpha and Beta were comparable, but Delta appears to be significantly more refractory to NAbs in all groups. Our results may help inform on CoronaVac NAb-inducing capacity, which is a proxy for vaccine efficacy, in the context of the WT strain and 3 VOCs. Our results also have critical implications for public health decision-makers who may need to maintain efficient mitigation strategies amid a potentially high risk for infection with VOCs even in those who have been previously infected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Research Council of Thailand, the Mahidol University for Integrated and Multidisciplinary Research Cluster grant (MRC-IM 02/2564), the Program Management Unit C, and the Ramathibodi Foundation. Funding sources had no involvement in study design, data collection, analysis or interpretation, nor in the writing of the manuscript and in the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All methods were performed following standard protocols approved by the institutional review committee. The study protocol and human ethics were approved by the Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital (COA. MURA2021/264) and the Ethics Committee of National Cancer Institute, Thailand (EC COA 019/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article